Identification of six new susceptibility loci for invasive epithelial ovarian cancer

Publikation: Bidrag til tidsskriftLetterForskningfagfællebedømt

  • Karoline B Kuchenbaecker
  • Susan J Ramus
  • Jonathan Tyrer
  • Andrew Lee
  • Howard C Shen
  • Jonathan Beesley
  • Kate Lawrenson
  • Lesley McGuffog
  • Sue Healey
  • Janet M Lee
  • Tassja J Spindler
  • Yvonne G Lin
  • Tanja Pejovic
  • Yukie Bean
  • Qiyuan Li
  • Simon Coetzee
  • Dennis Hazelett
  • Alexander Miron
  • Melissa Southey
  • Mary Beth Terry
  • David E Goldgar
  • Saundra S Buys
  • Ramunas Janavicius
  • Cecilia M Dorfling
  • Elizabeth J van Rensburg
  • Susan L Neuhausen
  • Yuan Chun Ding
  • Thomas V O Hansen
  • Lars Jønson
  • Gerdes, Anne-Marie Axø
  • Bent Ejlertsen
  • Daniel Barrowdale
  • Joe Dennis
  • Javier Benitez
  • Ana Osorio
  • Maria Jose Garcia
  • Ian Komenaka
  • Jeffrey N Weitzel
  • Pamela Ganschow
  • Paolo Peterlongo
  • Loris Bernard
  • Alessandra Viel
  • Bernardo Bonanni
  • Allan Jensen
  • Kjær, Susanne Krüger
  • Høgdall, Estrid Vilma Solyom
  • Høgdall, Claus Kim
  • Lene Lundvall
  • Lotte Nedergaard
  • Yu-Tang Gao
  • EMBRACE
Genome-wide association studies (GWAS) have identified 12 epithelial ovarian cancer (EOC) susceptibility alleles. The pattern of association at these loci is consistent in BRCA1 and BRCA2 mutation carriers who are at high risk of EOC. After imputation to 1000 Genomes Project data, we assessed associations of 11 million genetic variants with EOC risk from 15,437 cases unselected for family history and 30,845 controls and from 15,252 BRCA1 mutation carriers and 8,211 BRCA2 mutation carriers (3,096 with ovarian cancer), and we combined the results in a meta-analysis. This new study design yielded increased statistical power, leading to the discovery of six new EOC susceptibility loci. Variants at 1p36 (nearest gene, WNT4), 4q26 (SYNPO2), 9q34.2 (ABO) and 17q11.2 (ATAD5) were associated with EOC risk, and at 1p34.3 (RSPO1) and 6p22.1 (GPX6) variants were specifically associated with the serous EOC subtype, all with P < 5 × 10−8. Incorporating these variants into risk assessment tools will improve clinical risk predictions for BRCA1 and BRCA2 mutation carriers.
OriginalsprogEngelsk
TidsskriftNature Genetics
Vol/bind47
Udgave nummer2
Sider (fra-til)164-71, 3 unpag. p.
Antal sider11
ISSN1061-4036
DOI
StatusUdgivet - feb. 2015

ID: 161189420